GleamWall
中文EN

CPIX CUMBERLAND PHARMACEUTICALS INC

Pharmaceutical Preparations · Nasdaq · SEC CIK 1087294 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY10.7%
TTM net income YoY2,167.1%
TTM EPS YoY1,962.5%
Revenue 3-yr CAGR-13.9%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-38.2%
Net margin273.7%
FCF margin-3.9%
EBITDA margin-33.6%

Returns

ROE139.5%
ROA76.6%
ROIC (approx.)-532.4%
Asset turnover0.28x

Leverage & solvency

Liabilities / assets36.6%
Debt / equity0.00x
Current ratio3.05x
Interest coverage-47.02x

Cash quality & payout

Operating cash flow / net income-0.01x
Accruals ratio77.6%
Payout ratio—
Capex / revenue0.2%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302025Q12026-03-312025Q42025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q42024-12-31
Income statement
Revenue$2.16M$166,458$9.13M$13.68M$171,821$380,797$11.71M$10.44M
Cost of revenue——$1.93M$2.24M$988,760$2.01M$1.43M$1.98M
Gross profit——$7.20M$11.44M-$816,939-$1.63M$10.29M$8.46M
R&D expense$841,162$772,162$1.46M$1.55M$646,473$837,401$1.30M$1.29M
SG&A expense$2.18M$2.55M$2.55M$4.04M$2.38M$2.66M$2.46M$3.33M
Operating income-$1.94M-$3.16M-$3.13M-$1.37M-$2.86M-$3.12M$1.29M-$1.84M
Interest expense$4,604$724$85,839$112,942$29$471$163,802$223,261
Pretax income-$1.12M-$3.10M-$3.14M-$1.39M-$2.72M-$2.99M$1.25M-$1.96M
Income tax$3,871$3,870$3,871$23,245$5,670$5,671$5,670-$56,996
Net income$77.78M-$4.28M-$3.29M-$1.41M-$1.94M-$740,740$1.26M-$1.90M
EBITDA-$1.91M-$4.37M-$1.85M-$329,307-$2.83M-$2.09M$2.32M-$345,645
EPS (basic)5.19-0.29-0.22-0.09-0.13-0.050.08-0.14
EPS (diluted)5.07-0.29-0.22-0.09-0.13-0.050.08-0.14
Weighted avg. shares (diluted)15.34M14.98M14.96M—14.96M14.96M15.26M—
Balance sheet
Cash & equivalents$80.58M$3.86M$11.01M$11.44M$15.20M$16.09M$15.11M$17.96M
Receivables$2.13M$13.42M$14.26M$16.94M$10.43M$10.32M$10.49M$11.70M
Inventory$29,935$29,935$5.45M$29,935$2.93M$3.22M$4.10M$4.00M
Current assets$104.56M$33.64M$32.79M$37.06M$29.94M$31.21M$31.88M$36.45M
PP&E, net$232,154$248,808$237,375$264,724$293,375$297,793$298,740$277,365
Goodwill——$914,000$914,000$914,000$914,000$914,000$914,000
Intangibles$35,471$43,804$12.79M$53,621$15.01M$15.99M$16.99M$17.97M
Total assets$113.78M$62.88M$71.00M$76.82M$65.90M$67.91M$69.94M$75.58M
Current liabilities$34.33M$35.19M$34.49M$36.74M$24.31M$23.97M$25.52M$31.62M
Short-term debt———$0———$5.10M
Total liabilities$41.60M$45.77M$49.69M$52.28M$40.10M$40.23M$41.60M$53.04M
Shareholders' equity$72.51M$17.44M$21.64M$24.88M$26.12M$27.99M$28.66M$22.85M
Shares outstanding14.99M14.98M14.98M14.96M14.96M14.96M14.96M13.95M
Cash flow statement
Operating cash flow-$1.50M$168,740$387,025$3,024$187,179$843,801$3.90M$1.90M
Capital expenditure$9,812$38,283$0-$1$23,788$26,486$47,630$2,283
Free cash flow-$1.51M$130,457$387,025$3,025$163,391$817,315$3.85M$1.90M
Investing cash flow$100.08M-$1.93M-$61,173-$3.07M-$690,837$285,864-$1.23M-$26,809
Financing cash flow-$21.87M-$5.39M-$763,300-$681,738-$386,879-$150,797-$5.53M-$1.38M
Depreciation & amortization$30,304-$1.20M$1.28M$1.04M$21,555$1.03M$1.03M$1.50M
Stock-based compensation$8,083$77,866$106,842$172,160$81,262$80,686$74,212$74,812
Share buybacks$257,819$0$61,001$0$10,439$7,171$245,868$98,383

Free plan shows the latest 8 periods; Pro shows all 66 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.